Bridgefront Capital, LLC 4 D Molecular Therapeutics, Inc. Transaction History
Bridgefront Capital, LLC
- $236 Million
- Q2 2024
A detailed history of Bridgefront Capital, LLC transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Bridgefront Capital, LLC holds 10,171 shares of FDMT stock, worth $105,880. This represents 0.09% of its overall portfolio holdings.
Number of Shares
10,171Holding current value
$105,880% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding FDMT
# of Institutions
150Shares Held
56.3MCall Options Held
55.6KPut Options Held
167K-
Ra Capital Management, L.P. Boston, MA5.1MShares$53.1 Million1.61% of portfolio
-
Black Rock Inc. New York, NY4.9MShares$51 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY4.4MShares$45.8 Million10.13% of portfolio
-
Goldman Sachs Group Inc New York, NY4.13MShares$43 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.06MShares$42.3 Million2.8% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $337M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...